Skip to main content

Dexcom guidance

  • DXCM · Nasdaq
  • Medical devices
  • Health Care Equipment
  • S&P 500
$83.33+2.38%Close 13 Nov 2026 · Market value $30.72B

In its results release of 29 Oct 2026 (Q3 FY2026), Dexcom gave 4 forecasts in figures, among them revenue of $5.20B to $5.25B for FY2026. Over the last two years, results landed above the company's own last range 1 of 6 times, within it 3 and below it 2.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 29 Oct 2026

MeasurePeriodGuidanceAs stated
RevenueFY2026$5.20B to $5.25BRevenue of $5.20 - $5.25 billion (approximately 12-13% growth)
Revenue growthFY2026About +12% to +13%Revenue of $5.20 - $5.25 billion (approximately 12-13% growth)
Gross margin · AdjustedFY2026About 64%Non-GAAP Gross Profit Margin of approximately 64%
Operating margin · AdjustedFY2026About 24%Non-GAAP Operating Margin of approximately 24%

Source: the company's earnings release.

Guidance against results above 1 · within 3 · below 2

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$5.20B to $5.25BRaised twice—To come
Revenue growthFY2026About +12% to +13%Raised once—To come
Gross margin · AdjustedFY2026About 64%Raised once—To come
Operating margin · AdjustedFY2026About 24%Raised 3 times—To come
RevenueFY2025$4.63B to $4.65BRaised twice$4.66BAbove the range
Revenue growthFY2025About +15%Given once+15.6%Above the range
Gross margin · AdjustedFY2025About 61%Lowered twice60.8%Within the range
Operating margin · AdjustedFY2025About 20% to 21%Lowered once20.8%Within the range
RevenueFY2024About $4.00B to $4.05BGiven once$4.03BWithin the range
Gross margin · AdjustedFY2024About 63%Given once61.8%Below the range
Operating margin · AdjustedFY2024About 20%Given once18.8%Below the range

DXCM in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.